PCRX · Pacira BioSciences, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. Pacira reported Q2 2026 revenue of $192.4 million (+6% YoY) and adjusted EBITDA of $48.7 million, closed the iovera divestiture to Zimmer Biomet for up to $140 million, and lowered total revenue guidance to $735–$760 million (from $745–$770M) to reflect the divestiture while reiterating EXPAREL guidance of $600–$620 million amid softer elective soft tissue procedure volumes.
- + UnitedHealthcare now provides separate reimbursement for EXPAREL outside the surgical bundle, lifting covered lives to over 150 million.
- + EXPAREL net sales grew 3% to $147.8M and ZILRETTA grew 4% to $32.6M in Q2 2026.
- + LG Chem filed for EXPAREL approval in South Korea, with revenues expected to begin in 2027.
- + Cash position remains strong at $251.0 million as of June 30, 2026, further enhanced by $73.6M Zimmer closing payment.
- − Full-year 2026 total revenue guidance lowered to $735–$760 million from $745–$770 million due to iovera divestiture.
- − Elective soft tissue procedures slowed in Q2, pressuring Exparel volumes, particularly in hospital inpatient settings.
- − Non-GAAP gross margin fell to 78% in Q2 2026 from 82% in Q2 2025.
- − Non-GAAP net income of $29.5M ($0.73 diluted) in Q2 2026 declined from $36.0M ($0.74 diluted) in Q2 2025.
- − Adjusted EBITDA of $48.7 million in Q2 2026 declined from $54.3 million in Q2 2025.
- − SG&A increased to $81.3M in Q2 2026 from $77.2M in Q2 2025, partly due to non-recurring costs of contested director election.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PCRX
this stock
Pacira BioSciences, Inc.
|
$1.00B | -3.2% | +26.0% | — | 19.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +16.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -4.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.9% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -11.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PCRX | +1.7% | -5.4% | +5.2% | -3.3% | -3.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +2.4% | -5.5% | -7.0% | -2.7% | -15.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.